Copyright © 2014 San Francisco Hepatitis C Task Force. All rights reserved.

San Francisco Hepatitis C Task Force

San Francisco Hepatitis C Task Force

Addressing a silent epidemic.

2014 Task Force Membership
Co-Chairs
Robin Roth

Shirley Barger

Jim Banta

Kat Calloway
Stephanie Catella
Misha Cohen
Peter Dale
Ray Goldstein
Pauli Gray
Madeline Griffis 
Theresa Hughes

  • Hepatitis is  inflammation of the liver and the disease includes a group of viral infections..
  • The most common types are hepatitis A, hepatitis B and hepatitis C.
  • The Hepatitis C virus (HCV) infects and can severely damage the liver. It is the most common chronic blood borne disease in the United States; approximately 4-6 million persons are infected.
  • San Francisco has the highest liver cancer rate in the nation, most of which is attributed to high rates of hepatitis B and hepatitis C virus infections.
  • In 2009, Mayor Gavin Newsom appointed a diverse group of individuals to form the San Francisco Hepatitis C Task Force and to develop recommendations about how to address hepatitis C in the city. Since 2010 the Task Force has been meeting monthly.


Monday, November 10, 2014
5:30pm - 7:30pm

Location:

San Francisco Department of Public Health

25 Van Ness Avenue, 6th Floor

San Francisco

Contact info@sfhepc.org

Don't Go Viral

Get Tested

Get Cured

Hepatitis Testing available at:

Transgender Health Fair

San Francisco Main Library

Civic Center

Wednesday Nov 19, 2014

1 PM - 3 PM

Liver Life Walk 2014

Debbie, Daniel, Shirley and Susan

Newest treatment for Hep C Genotype 1

                 The U.S. Food and Drug Administration (FDA) approved Gilead's Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Harvoni combines the nucleotide analog polymerase inhibitor Sovaldi® (sofosbuvir), approved in December 2013, with ledipasvir, an NS5A inhibitor.